Topics:
Hematologic Malignancies • Medical Oncology • Myeloma • NCI-CCC Tumor Board Question • Mayo Clinic • NCI-CCC Myeloma Tumor Board Question • Multiple Myeloma
Do you recommend utilizing daratumumab in the maintenance phase after a quadruplet induction for transplant eligible multiple myeloma?
Answer from: Medical Oncologist at Academic Institution
Great question as always - both the Phase 2 GRIFFIN study (Dara-VRd vs VRd using IV Dara and 21-day induction cycles) and the Phase 3 PERSEUS study (Dara-VRd vs VRd using subQ dara and 28-day induction cycles) went on to use dara + lenalidomide for all patients in the post-transplant maintenance set...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Dr. @Banerjee has summarized the data well. The phrase "standard-risk cytogenetics" has not aged well, and I am hoping that more precise language will be more commonplace, incorporating the influence of increased LDH, 1q+, del 1p, circulating plasma cells, etc.While Dara+Len is not yet as well suppo...
Answer from: Medical Oncologist at Academic Institution
I think Dr. @Banerjee has summarized things well. One additional point I will make is that the Emory group presented on a very large series of patients treated with Dara-VRd and transplant, after which standard-risk patients received only lenalidomide and high-risk patients received a PI/IMiD. The P...